158 related articles for article (PubMed ID: 33378542)
1. Towards novel reimbursement models for expensive advanced therapy medicinal products (ATMPs).
Picecchi D; Bertram K; Brücher D; Bauer M
Swiss Med Wkly; 2020 Dec; 150():w20355. PubMed ID: 33378542
[TBL] [Abstract][Full Text] [Related]
2. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
[TBL] [Abstract][Full Text] [Related]
3. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
4. Managing access to advanced therapy medicinal products: Challenges for NHS Wales.
Champion AR; Lewis S; Davies S; Hughes DA
Br J Clin Pharmacol; 2021 Jun; 87(6):2444-2449. PubMed ID: 32495405
[TBL] [Abstract][Full Text] [Related]
5. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
6. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
7. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England.
Ten Ham RMT; Frederix GWJ; Wu O; Goettsch W; Leufkens HGM; Klungel OH; Hoekman J
Value Health; 2022 Mar; 25(3):390-399. PubMed ID: 35227451
[TBL] [Abstract][Full Text] [Related]
8. Emerging technologies for quality control of cell-based, advanced therapy medicinal products.
Zia S; Pizzuti V; Paris F; Alviano F; Bonsi L; Zattoni A; Reschiglian P; Roda B; Marassi V
J Pharm Biomed Anal; 2024 Aug; 246():116182. PubMed ID: 38772202
[TBL] [Abstract][Full Text] [Related]
9. RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe-Why the European Union Should Invest More!
Goldsobel G; von Herrath C; Schlickeiser S; Brindle N; Stähler F; Reinke P; Aberman Z; Ofir R; Dessole G; Benvenuti S; Neves NM; Reis RL; Moll G; Volk HD
Front Med (Lausanne); 2021; 8():739987. PubMed ID: 34765617
[TBL] [Abstract][Full Text] [Related]
10. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
11. State-of-the-art knowledge on the regulation of advanced therapy medicinal products.
Kidpun P; Ruanglertboon W; Chalongsuk R
Per Med; 2022 May; 19(3):251-261. PubMed ID: 35293224
[TBL] [Abstract][Full Text] [Related]
12. Advanced therapy medicinal products: current and future perspectives.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
[TBL] [Abstract][Full Text] [Related]
13. Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs).
Spoors J; Miners A; Cairns J; Palnoch D; Summerfield A; McEntee J; Vithlani S
BioDrugs; 2021 Jan; 35(1):1-5. PubMed ID: 33226582
[TBL] [Abstract][Full Text] [Related]
14. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.
Rejon-Parrilla JC; Espin J; Garner S; Kniazkov S; Epstein D
Front Pharmacol; 2023; 14():1199500. PubMed ID: 38089054
[No Abstract] [Full Text] [Related]
15. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.
Gonçalves E
Eur J Health Econ; 2020 Apr; 21(3):311-320. PubMed ID: 31919703
[TBL] [Abstract][Full Text] [Related]
16. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
17. Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion.
Horgan D; Metspalu A; Ouillade MC; Athanasiou D; Pasi J; Adjali O; Harrison P; Hermans C; Codacci-Pisanelli G; Koeva J; Szucs T; Cursaru V; Belina I; Bernini C; Zhuang S; McMahon S; Toncheva D; Thum T
Biomed Hub; 2020; 5(3):130-152. PubMed ID: 33987187
[TBL] [Abstract][Full Text] [Related]
18. Paying for quality not quantity: a wisconsin health maintenance organization proposes an incentive model for reimbursement of chiropractic services.
Pursel KJ; Jacobson M; Stephenson K
J Manipulative Physiol Ther; 2012 Jul; 35(6):472-6. PubMed ID: 22926019
[TBL] [Abstract][Full Text] [Related]
19. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.
Jönsson B; Hampson G; Michaels J; Towse A; von der Schulenburg JG; Wong O
Eur J Health Econ; 2019 Apr; 20(3):427-438. PubMed ID: 30229376
[TBL] [Abstract][Full Text] [Related]
20. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
